University of Texas Rio Grande Valley ScholarWorks @ UTRGV

Research Symposium

Evaluation of ergosterol and its metabolites as LXR agonists and their anticancer potential in colon cancer

Yogain Taank Panjab University, Chandigarh, India, yogaintaank@gmail.com

Navneet Agnihotri Panjab University, Chandigarh, India, agnihotri.navneet@gmail.com

Follow this and additional works at: https://scholarworks.utrgv.edu/somrs

Part of the Biochemistry Commons

Recommended Citation

Taank, Yogain and Agnihotri, Navneet, "Evaluation of ergosterol and its metabolites as LXR agonists and their anticancer potential in colon cancer" (2024). *Research Symposium*. 9. https://scholarworks.utrgv.edu/somrs/2024/posters/9

This Poster is brought to you for free and open access by ScholarWorks @ UTRGV. It has been accepted for inclusion in Research Symposium by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu, william.flores01@utrgv.edu.

Evaluation of ergosterol and its metabolites as LXR agonists and their anticancer potential in colon cancer

Yogain Taank¹, Navneet Agnihotri^{1*}

1. Department of Biochemistry, Panjab University, Chandigarh, India

*Corresponding author's e-mail: <u>navneet_agnihotri@pu.ac.in</u> <u>First author's email: yogaintaank@gmail.com</u>

ABSTRACT

Purpose: Aberrant cholesterol homeostasis is a well-recognized hallmark of cancer and implicated in metastasis and chemotherapeutic resistance, the two major causes of cancer associated mortality. Liver X receptors (LXRs) are the key transcription factors that induce cholesterol efflux via enhancing the expression of ABCA1 and ABCG1.

Methods: Molecular docking and dynamic simulation studies were done to assess the binding affinity and stability of the receptor ligand complexes. Activation of LXRs was evaluated using the luciferase reporter assay. qRT-PCR and western blotting was done to analyse the mRNA and protein expression of cholesterol homeostasis genes. Flow cytometric analysis was carried out to evaluate the surface expression of ABCA1. The effect of selected sterols on viability of three cancer cell lines and one normal epithelial cell line was assessed using MTT assay.

Results: Ergosterol (Erg), ergosta-7,22,24(28)-trien-3β-ol (Erg1), ergosta-5,22,25-trien-3-ol (Erg2), ergosta-5,7,22,24(28)-tetraen-3β-ol (Erg3), and ergosta-7,22-dien-3β-ol (Erg4) displayed good binding affinities and formed stable complexes with both isoforms of LXRs. Treatment with Erg led to 2.5 fold while Erg2 and Erg4 led to 1.7 fold increase in LXR activation. Furthermore, a significant increase in mRNA expression of *NR1H2*, *ABCA1*, *ABCG1* and *ApoE* was observed upon Erg treatment and it also led to a 25 fold increase in cell surface expression of ABCA1. All of the sterol were selectively toxicity toxic towards colorectal cancer cells but not towards normal epithelial cells.

Conclusion: Our findings suggests that ergosterol activates $LXR\beta$ and have significant anticancer activity and thus it could be a likely candidate to manage aberrant cholesterol homeostasis associated with colorectal cancer.